CD8A and myeloid sarcoma: Based on the metabolic reprogramming induced by 6AN in CD8+ T cells and the phenotypic differences induced by 6AN pretreatment in the adoptive transfer experiment, we hypothesized that this drug would reduce or prevent functional deficits in the EAE mouse model of MS.